Johnson & Johnson Acquires V-Wave for Up to $1.7 Billion to Expand Heart Failure Therapeutics Portfolio

Atrial septal shunt technology is a new technology for treating heart failure that has emerged internationally in recent years. Currently, in this field, only products from three companies worldwide have been approved by the European Union. There are still no related products approved for marketing in China and the United States, and China is also in the early stages of research and development in this area.

Local time on August 20,Johnson & JohnsonCompany Announces Acquisition of Israeli Heart Failure Implantable Medical Device Company V-Wave for Up to $1.7 Billion. This follows Johnson & Johnson's acquisition of Shockwave for approximately $13 billion in April this year, marking another strategic move in the cardiovascular field.

V-Wave, which specializes in interatrial shunt technology, represents a new approach in the treatment of heart failure that has emerged internationally in recent years. Currently, only three companies worldwide have products approved by the EU in this field, and no such products have been approved for marketing in either China or the United States. China is also in the stage of accelerating the development of related technologies.

V-Wave's cardiovascular implant technology specifically targets heart failure with reduced ejection fraction (HFrEF). The company’s atrial shunt device (IAS) Ventura can reduce elevated left atrial pressure associated with congestive heart failure by creating a shunt between the left and right atria, thereby decreasing cardiovascular events and hospitalization rates for heart failure. It is expected to become a complementary therapy to artificial heart implantation.

In China, publicly available information shows that companies including V-Wave, Lepu CardioTech, NISI Medical, Qichen Medical, and Aolian Medical are all developing related atrial shunt devices. Reporters from the First Financial learned that among them, the domestically produced atrial shunt device independently developed by V-Wave is expected to obtain certification as early as next year, but it still needs to undergo rigorous randomized controlled trials (RCT).

An expert engaged in the research and development of atrial shunt devices told the First Financial Daily: "The atrial shunt device can not only significantly improve the clinical symptoms of heart failure patients, but there is also evidence showing that its efficacy is superior to existing heart failure drugs when appropriate patients are selected. Moreover, from a hemodynamic perspective, this medical device reduces the preload on the left ventricle, aligning with modern concepts of heart failure treatment. Therefore, theoretically, it should extend patient survival and provide a novel treatment strategy for mid-to-late stage heart failure patients."

Heart failure has always been a clinical challenge, known as the "final battlefield" of cardiovascular diseases. Heart failure represents the end stage of various cardiovascular diseases and is characterized by poor prognosis, limited treatment options, and high patient mortality. Patients with heart failure often require hospitalization, and their quality of life is significantly reduced, with more than half of patients dying within five years.

Approximately 2% of adults worldwide suffer from heart failure, with the prevalence increasing with age. Data from the "Report on Cardiovascular Health and Diseases in China" estimates that there are as many as 12.1 million heart failure patients in China, and the incidence rate is still increasing annually.

Professor Shen Li from the Cardiology Department of Zhongshan Hospital, Fudan University, told the First Financial Journalist that the 2024 edition of the guidelines recommends the "new quadruple drug therapy" for patients with chronic heart failure. While these therapies are effective, they still cannot treat all cases of heart failure, especially end-stage heart failure.

Some experts also believe that atrial shunt devices merely offer a "palliative care" solution for end-stage heart failure patients. In this regard, Shen Li stated: "Atrial shunt devices can alleviate symptoms in patients to a certain extent, but more clinical data is still needed for validation."

Editor: Liu Mingliang